Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results.
Three years of gene therapy tracking shows sustained micro-dystrophin production, offering hope for slowing Duchenne muscular dystrophy progression in treated patients.
This phase iii clinical trial evaluated Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results. The abstract reports Delandistrogene moxeparvovec, an adeno-associated virus vector-based gene therapy, delivers an optimized micro-dystrophin transgene to address dystrophin deficiency in Duchenne muscular dystrophy (DMD).
What the study was
- Study design
- Phase III clinical trial
- Population
- Human participants or patients described in the PubMed abstract
- Sample size
- 64
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Neurol Ther
Why it surfaced
Phase III clinical trial; PubMed abstract reviewed; conservative score reflects design, direct relevance, and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.